echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > The latest clinical application of Eltanexor in the treatment of MDS refractory to demethylation drugs...

    The latest clinical application of Eltanexor in the treatment of MDS refractory to demethylation drugs...

    • Last Update: 2021-06-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 9th, Karyopharm Therapeutics, a partner of Deqi Pharmaceuticals, announced at the 2021 American Society of Clinical Oncology (ASCO) annual meeting that eltanexor was used to treat myelodysplastic syndrome (MDS) refractory to demethylation drugs (HMA).


    The trial is a phase I/II clinical study aimed at evaluating single-agent eltanexor in the treatment of higher-risk MDS patients, that is, according to the International Prognostic Scoring System (IPSS) assessed as intermediate-risk-2 or high-risk MDS patients, and the proportion of bone marrow blasts It is 5-19%


    Among the 20 patients enrolled in the group, 15 patients can be evaluated for efficacy


    MDS patients refractory to demethylation drugs have limited treatment options and poor prognosis.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.